BioSpace News Archive

Sorrento Therapeutics, Inc. announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento’s employee wages motion and interim approval of its cash management motion, in connection with Sorrento’s chapter 11 petition, which was filed on February 13, 2023.

Singular Genomics Systems, Inc. announced that it will report financial results for the fourth quarter 2022 after the market close on Thursday, March 2, 2023.

Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2022 financial results prior to the market open on Friday, March 3, 2023.

Jasper Therapeutics, Inc. announced that additional follow-up data from Jasper’s investigator-sponsored study of briquilimab as a conditioning agent in the treatment of sickle cell disease were presented in a plenary session focused on novel antibody-based conditioning regimens at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.

Vir Biotechnology, Inc. announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023.

Predicine, a global molecular insights company, is committed to advancing genitourinary cancer detection and treatment decisions through its proprietary non-invasive next-generation sequencing assays.

Sage Therapeutics, Inc. reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.

Pfizer Inc. announced publication of results in The Lancet Neurology from the Phase 3 pivotal clinical trial of zavegepant, an investigational calcitonin gene-related peptide receptor antagonist nasal spray for the acute treatment of migraine.

Applied Therapeutics, Inc. announced positive sorbitol reduction data from the ongoing global Phase 3 INSPIRE trial.